# Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

> **NCT01681095** · PHASE2 · COMPLETED · sponsor: **Marc Sakwa, MD** · enrollment: 110 (actual)

## Conditions studied

- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Heart Diseases
- Valvular Heart Disease

## Interventions

- **DRUG:** Custodiol HTK
- **DRUG:** Cold Blood Cardioplegia

## Key facts

- **NCT ID:** NCT01681095
- **Lead sponsor:** Marc Sakwa, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-08
- **Final completion:** 2016-04
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01681095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01681095, "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01681095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*